Actively Recruiting
Evaluating Entecavir 0.5 mg Versus 1.0 mg Daily for Men with Decompensated Hepatitis B Cirrhosis
Led by Bangladesh Medical University · Updated on 2026-09-11
48
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the antiviral effects and safety of two different daily doses of entecavir, 0.5 mg and 1.0 mg, in adult men with hepatitis B virus-related decompensated liver cirrhosis. This phase 4, randomized, open-label clinical trial aims to compare how well these doses suppress the hepatitis B virus over 24 weeks. Participants are randomly assigned to receive either 0.5 mg or 1.0 mg of oral entecavir once daily for 24 weeks. Both groups receive the study drug under medical supervision, and no placebo is used. The trial focuses on monitoring the reduction of hepatitis B virus DNA levels as the primary measure of antiviral effectiveness. During the study, participants will be closely monitored for changes in liver function scores, viral markers, and any development or worsening of liver complications, including liver cancer. Researchers will assess safety and side effects throughout the 24-week treatment period. The main outcome is the change in serum HBV DNA from the start to week 24.
CONDITIONS
Brief Title
Comparison of Viral Suppression With 0.5 mg and 1.0 mg Daily Doses of Entecavir in Decompensated HBV Cirrhosis of Liver
Research Team
H
Hanif Uddin, MBBS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here